GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Equity-to-Asset

NXTC (NextCure) Equity-to-Asset : 0.81 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NextCure's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $65.47 Mil. NextCure's Total Assets for the quarter that ended in Dec. 2024 was $80.86 Mil.

The historical rank and industry rank for NextCure's Equity-to-Asset or its related term are showing as below:

NXTC' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.25   Med: 0.9   Max: 0.96
Current: 0.81

During the past 8 years, the highest Equity to Asset Ratio of NextCure was 0.96. The lowest was -1.25. And the median was 0.90.

NXTC's Equity-to-Asset is ranked better than
69.37% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs NXTC: 0.81

NextCure Equity-to-Asset Historical Data

The historical data trend for NextCure's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Equity-to-Asset Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial 0.96 0.96 0.91 0.89 0.81

NextCure Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.86 0.83 0.84 0.81

Competitive Comparison of NextCure's Equity-to-Asset

For the Biotechnology subindustry, NextCure's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCure's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NextCure's Equity-to-Asset falls into.


;
;

NextCure Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NextCure's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=65.472/80.86
=

NextCure's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=65.472/80.86
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure  (NAS:NXTC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


NextCure Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of NextCure's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCure Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Executives
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw officer: Sr VP, Legal Affairs 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu officer: Sr VP, Dev. & Mfg. 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint officer: Chief Medical Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer officer: Chief Operating Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann officer: Chief Scientific Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn officer: Chief Financial Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu officer: SVP, Research C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman director, officer: President & CEO 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025